A predictive nomogram for progression-free survival in radioiodine-refractory papillary thyroid carcinoma after reoperation: a longitudinal study in Vietnam

Endocrine Journal, 2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.1507/endocrj.ej25-0565
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

and TERT promoter mutations (Dmut). The hazard ratios (95% confidence intervals) were 3.86 (1.54-9.72) for biochemical incomplete response, 9.39 (3.35-26.3) for structural incomplete response, 3.40 (1.69-6.85) for extrathyroidal/extranodal extension, 1.34 (1.13-1.58) for mitotic count, and 6.08 (2.79-13.2) for Dmut. The optimal model demonstrated strong discriminative performance and stability across time points, with AUCs (95% confidence intervals) of 0.905 (0.801-1.000), 0.919 (0.857-0.981), and 0.921 (0.861-0.981) at 12, 24, and 36 months, respectively, and showed good calibration. This study demonstrates that integrating treatment response, extrathyroidal/extranodal extension, mitotic count, and Dmut into a predictive nomogram offers a clinically relevant tool for stratifying progression risk in patients with RAI-R PTC.